Therapy News and Research

RSS

$Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports$

Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports

Osteoporosis is a disease of the bones usually affecting elderly women and causes the bones to become brittle and easily breakable. Since last two years some alarming reports of women on drugs for therapy of this disease have come to notice. These reports show that these drugs intended for therapy may result in rare and serious fractures of their thigh bones where the bones break clean or may splinter. Often these fractures were not associated with any fall or impact. Moreover some of the sufferers are middle aged women in their 50’s who do not have full blown osteoporosis, a condition known as pre-osteoporosis or osteopenia.

25 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

NHS needs to gear up in terms of productivity, say statisticians

In an alarming new revelation, the productivity of National Health Service NHS, has dropped steadily from 2001 by 0.4% each year and a total of 3%. 2008 has seen the largest fall, 0.7% according to the Office for National Statistics, ONS.

25 Mar 2010

Biocompatible electronics could enable new surgical applications

Arrhythmic hearts soon may beat in time again, with minimal surgical invasion, thanks to flexible electronics technology developed by a team of University of Illinois researchers, in collaboration with the University of Pennsylvania School of Medicine and Northwestern University.

25 Mar 2010

Changing drug therapy can help breast cancer patients get full benefit of Tamoxifen

Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an important enzyme. Now researchers have developed a strategy for overcoming this problem, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today (Wednesday).

25 Mar 2010

Anesthesia can increase behavioral changes, risk of developing Alzheimer's disease

The use of repetitive anesthesia with isoflurane (one of the most common anesthetics by inhalation) increases the risk of developing changes similar to those observed in AD brains in mice with mutations of the amyloid precursor protein (APP). This is the main conclusion of Spanish researchers coordinated by Doctors Maria -ngeles Mena and Justo Garc-a de Y-benes, from CIBERNED (Centro de Investigaci-n Biom-dica en Red de Enfermedades Neurodegenerativas).

25 Mar 2010

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Gastric bypass surgery, thought of by many as the last hope of morbidly obese people for losing weight, has many other benefits researchers are only beginning to understand.

25 Mar 2010

Special medicated contact lenses can help treat common eye disorders

The popular dietary supplement vitamin E, loaded into special medicated contact lenses, can keep glaucoma medicine near the eye - where it can treat that common disease- almost 100 times longer than possible with current commercial lenses, scientists reported here today.

25 Mar 2010

Study: MetAP inhibitors prevent TB growth in test tubes

Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria's survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein's activity and, in a test tube, blocks TB growth, demonstrating that the protein is indeed a vulnerable target.

25 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

New injection device for endoscopic treatment of pediatric vesicoureteral reflux

A new injection device for the endoscopic treatment of vesicoureteral reflux) offers urologists greater control, precision and accuracy for treating a condition of the urinary tract that predominantly affects infants and young children. An alternative to corrective surgery, the Injekt VUR Injection Needle marks an advancement in fast and minimally-invasive endoscopic treatment.

24 Mar 2010

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis. Thirty-two percent of surveyed dermatologists selected Humira as the most efficacious, followed by Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade. The current sales leader Amgen/Pfizer/Takeda's Enbrel was selected as the most efficacious therapy by only 23 percent of dermatologists surveyed.

24 Mar 2010

Teletherapy as effective as face-to-face session

Obtaining therapy via teleconference is just as effective as face-to-face sessions, according to a new research by St-phane Guay, a psychiatry professor at the Universit- de Montr-al.

24 Mar 2010

TYRX begins enrollment in CITADEL study for Aigisrx anti-bacterial agent

TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce infection, announced today that it has begun enrollment in CITADEL, the second of two large scale, prospective, multicenter studies.

24 Mar 2010

Bone stem cells could become a part of new, innovative hip replacement treatment

Bone stem cells could in future be used instead of bone from donors as part of an innovative new hip replacement treatment, according to scientists at the University of Southampton.

24 Mar 2010

RCOG prostate cancer treatment database reaches new milestone

Radiotherapy Centers of Georgia (RCOG), a division of RC Cancer Centers announced today that they have reached a new milestone and recently treated their 12,500th patient for prostate cancer with their ProstRcision® treatment therapy.

24 Mar 2010

Med-Vision provides strategies to lower healthcare costs, improve quality

Med-Vision, a Tampa-based medical consulting company providing strategies to lower healthcare costs and improve quality of care, is providing free healthcare planning advice and solutions via the Web. A newly launched Insights on Healthcare Blog (http://medvision.wordpress.com/) created by Dan Ross, president of Med-Vision, offers timely healthcare commentary, insights to help healthcare consumers, and information to help self-funded employers understand complicated issues of employee benefits.

24 Mar 2010

AHF to protest against Merck's pricing of Isentress

AIDS Healthcare Foundation will host a protest Wednesday morning, March 24th at 10:30am targeting Merck and Co. Pharmaceuticals over the pricing and policies for its key HIV/AIDS drug, Isentress, one of the most expensive first-line AIDS treatment in the US, during the Barclays Capital Global Healthcare Conference.

24 Mar 2010

Massages help bereaved relatives move forward with their lives

Receiving soothing massages for eight weeks after the death of a loved one can provide much-needed consolation during an intense, stressful period of grieving, according to a study in the April issue of the Journal of Clinical Nursing.

24 Mar 2010

Therapy News and Research

Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

NHS needs to gear up in terms of productivity, say statisticians

Biocompatible electronics could enable new surgical applications

Changing drug therapy can help breast cancer patients get full benefit of Tamoxifen

Anesthesia can increase behavioral changes, risk of developing Alzheimer's disease

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Special medicated contact lenses can help treat common eye disorders

Study: MetAP inhibitors prevent TB growth in test tubes

Æterna Zentaris announces 2009 financial and operating results

New injection device for endoscopic treatment of pediatric vesicoureteral reflux

Abbott/Eisai's Humira termed as most efficacious therapy for psoriasis

Teletherapy as effective as face-to-face session

TYRX begins enrollment in CITADEL study for Aigisrx anti-bacterial agent

Bone stem cells could become a part of new, innovative hip replacement treatment

RCOG prostate cancer treatment database reaches new milestone

Med-Vision provides strategies to lower healthcare costs, improve quality

AHF to protest against Merck's pricing of Isentress

Massages help bereaved relatives move forward with their lives

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News